Alnylam Pharmaceuticals (ALNY) Given “Neutral” Rating at Goldman Sachs Group

Goldman Sachs Group reiterated their neutral rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report released on Thursday morning, BenzingaRatingsTable reports. They currently have a $80.00 price objective on the biopharmaceutical company’s stock.

Several other brokerages also recently issued reports on ALNY. BidaskClub downgraded shares of Alnylam Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, May 9th. Zacks Investment Research downgraded shares of Alnylam Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, May 8th. Morgan Stanley set a $126.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a report on Thursday, May 2nd. BMO Capital Markets upped their price target on shares of Alnylam Pharmaceuticals from $126.00 to $128.00 and gave the stock an outperform rating in a report on Thursday, May 2nd. Finally, Stifel Nicolaus upped their price target on shares of Alnylam Pharmaceuticals from $110.00 to $116.00 and gave the stock a buy rating in a report on Monday, April 15th. Two analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of Buy and an average target price of $127.44.

Shares of ALNY opened at $68.93 on Thursday. Alnylam Pharmaceuticals has a one year low of $60.27 and a one year high of $124.21. The company has a market cap of $7.34 billion, a price-to-earnings ratio of -9.11 and a beta of 2.53. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.33 and a quick ratio of 9.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) EPS for the quarter, beating the consensus estimate of ($2.20) by $0.47. Alnylam Pharmaceuticals had a negative net margin of 929.51% and a negative return on equity of 55.33%. The business had revenue of $33.29 million during the quarter, compared to the consensus estimate of $21.60 million. During the same period in the previous year, the business earned ($1.22) earnings per share. The company’s revenue was up 52.0% on a year-over-year basis. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -8.48 earnings per share for the current fiscal year.

In related news, Director Philip A. Sharp sold 15,000 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $88.23, for a total value of $1,323,450.00. Following the completion of the sale, the director now directly owns 250,633 shares in the company, valued at $22,113,349.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Maraganore sold 49,457 shares of the company’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $70.00, for a total transaction of $3,461,990.00. Following the sale, the chief executive officer now directly owns 239,450 shares in the company, valued at approximately $16,761,500. The disclosure for this sale can be found here. Corporate insiders own 3.60% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of ALNY. Meeder Asset Management Inc. boosted its position in Alnylam Pharmaceuticals by 332.9% during the first quarter. Meeder Asset Management Inc. now owns 342 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 263 shares during the last quarter. US Bancorp DE boosted its position in Alnylam Pharmaceuticals by 66.2% during the first quarter. US Bancorp DE now owns 369 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 147 shares during the last quarter. Quadrant Capital Group LLC boosted its position in Alnylam Pharmaceuticals by 543.2% during the first quarter. Quadrant Capital Group LLC now owns 521 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 440 shares during the last quarter. Flagship Harbor Advisors LLC bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at $47,000. Finally, FUKOKU MUTUAL LIFE INSURANCE Co boosted its position in Alnylam Pharmaceuticals by 40.0% during the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 700 shares of the biopharmaceutical company’s stock valued at $51,000 after acquiring an additional 200 shares during the last quarter. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

See Also: Strangles

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.